Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells (Q45417679)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 April 2006

Language	Label	Description	Also known as
English	Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells	scientific article published on 17 April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells (English)

1 reference

Europe PubMed Central

14 December 2017

author name string

Ralf Arnold

1

1 reference

Europe PubMed Central

14 December 2017

Wolfgang König

2

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

17 April 2006

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

350

1 reference

Europe PubMed Central

14 December 2017

2

1 reference

Europe PubMed Central

14 December 2017

335-346

1 reference

Europe PubMed Central

14 December 2017

Respiratory syncytial virus infection of human lung endothelial cells enhances selectively intercellular adhesion molecule-1 expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

'PPAR'ting ways with inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

PPAR-gamma agonists as therapy for diseases involving airway neutrophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Inhibition of respiratory viruses by nasally administered siRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Epithelial cells infected with respiratory syncytial virus are resistant to the anti-inflammatory effects of hydrocortisone.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Inhibition of IFN-gamma-mediated inducible nitric oxide synthase induction by the peroxisome proliferator-activated receptor gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, involves inhibition of the upstream Janus kinase/STAT1 signaling pathw

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Orally active fusion inhibitor of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Development of a quantitative TaqMan RT-PCR for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

PPARs and the complex journey to obesity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Impact of respiratory virus infections on persons with chronic underlying conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Management of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial virus infection activates STAT signaling in human epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

ERK-1/2 activity is required for efficient RSV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Identification of NF-kappaB-dependent gene networks in respiratory syncytial virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

In vivo selection of respiratory syncytial viruses resistant to palivizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.03.008

7 January 2021

Identifiers

10.1016/J.VIROL.2006.03.008

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45417679&oldid=2076882996"